FluoGuide (FLOU) investor relations material

Executive summary

• No revenues reported as the company remains in development, focusing on R&D and clinical trial progress, with FDA authorization for the first U.S. Phase II trial in high-grade glioma and Fast Track designation granted.

• Key clinical milestones include IND submission, authorization for U.S. phase II study in high-grade glioma, and final patient enrollment in the head and neck cancer trial.

• FG001 demonstrated positive clinical results in multiple tumor types and is positioned as a differentiated platform for fluorescence-guided oncology surgery.

• Execution of strategic plans and clinical trial enrollment remain central themes for 2026, with focus on expanding into additional brain and head & neck cancer indications.

• Fast Track designation reflects recognition of unmet medical need and potential for expedited development.

Financial highlights

• Net result for Q1 2026 was a loss of DKK 11.8 million, with no net revenue reported and other operating income at DKK 54 thousand.

• R&D costs for the quarter were DKK 8.6 million (including DKK 5.7 million specifically reported), staff costs DKK 4.6 million, admin costs DKK 1.9 million, and sales & marketing DKK 928 thousand.

• Cash and securities at period end were DKK 63.2 million, with total assets DKK 76 million and equity at DKK 43.1 million.

• Cash flow for the period was negative DKK 15.6 million, mainly due to operational expenses.

• Tax credits from last year and current period total DKK 8 million.

Outlook and guidance

• Cash runway expected to last until end of Q1 2027, with increased R&D spending aligned with plans.

• Execution of clinical and strategic plans is emphasized as the main focus for 2026, including U.S. registration trials and at least one new partnership.

• Interim results for the head and neck CT-005 trial expected in June, with further milestones anticipated in the second half.

• Long-term objectives target first U.S. approval for FG001 and expansion into broader oncology surgery markets.